Sanofi

Québec invests in public-private partnership for personalized cancer medicine

Wednesday, February 20, 2013 10:55 AM

The Québec government has invested $10 million in the Personalized Medicine Partnership for Cancer (PMPC), a public-private partnership focused on establishing an integrated approach for the development and implementation of clinical biomarkers and other personalized healthcare solutions to improve the outcome and cost-efficiency of healthcare services provided to cancer patients.

More... »


$262M Pan-European drug discovery platform launched

Friday, February 8, 2013 10:48 AM

The European Lead Factory, a novel platform for innovative drug discovery, was launched Feb. 7 by an international consortium of 30 partners. The partnership, the first of its kind, is supported by the Innovative Medicines Initiative (IMI) and creates opportunities for the discovery of new medicines by providing public partners with an “industry-like” discovery platform to translate cutting-edge academic research into high-quality drug lead molecules on a scale and speed that was not possible previously.

More... »


Prize4Life launches PRO-ACT, largest ALS trials database ever created

Friday, December 7, 2012 10:42 AM

Prize4Life, a nonprofit organization dedicated to accelerating discovery of treatments and a cure for ALS (amyotrophic lateral sclerosis, also known as Lou Gehrig's disease), launched the PRO-ACT (Pooled Resource Open-Access ALS Clinical Trials) database, the largest ALS clinical trial database ever created.

More... »

Selecta, Sanofi to develop antigen-specific immunotherapies for life-threatening allergies

Friday, November 30, 2012 10:55 AM

Selecta Biosciences, a Watertown, Mass.-based clinical-stage biopharmaceutical company developing a new class of synthetic vaccines and immunotherapies, has entered into a strategic global collaboration with global healthcare company Sanofi to discover highly targeted, antigen-specific immunotherapies for life-threatening allergies.

More... »

Sanofi, T1D Exchange to investigate optimal care for young people with diabetes

Friday, November 16, 2012 02:06 PM

Sanofi, a global healthcare comapny, and T1D Exchange, a non-profit organization focused on type 1 diabetes, will collaborate on the TEENs registry study, which aims to provide the type 1 diabetes community with a better understanding of how children, adolescents and young adults are currently living with type 1 diabetes, and to deliver recommendations for better disease management and patients outcomes.

More... »

CEO of Sanofi designated as new president elect of EFPIA

Wednesday, November 7, 2012 01:55 PM

The European Federation of Pharmaceutical Industries and Associations (EFPIA), which represents the pharmaceutical industry operating in Europe, has designated Christopher A. Viehbacher, CEO of Sanofi, as the new president elect of EFPIA. He will take up the position as of June 2013 for a two year term.

More... »

Theratechnologies revises business plan, cuts 15 employees

Wednesday, October 31, 2012 10:39 AM

Theratechnologies, a Canadian specialty pharmaceutical company focused on therapeutic peptide products, has revised its business plan which will focus on revenue growth from tesamorelin in the short term and expenditure control.

More... »

Sanofi, Mass. General Hospital launch oncology research collaboration

Thursday, October 11, 2012 07:00 AM

Global healthcare company Sanofi has formed a two-year agreement with Massachusetts General Hospital (MGH) aimed at furthering translational medicine research to develop new treatments for various types of hematological malignancies and solid tumors.

More... »

BMS, Sanofi restructure alliance agreement

Thursday, October 4, 2012 10:36 AM

Global biopharmaceutical company Bristol-Myers Squibb and global healthcare company Sanofi have restructured their successful long-term alliance following the loss of exclusivity of Plavix and Avapro/Avalide in many major markets.

More... »

Sanofi to acquire Genfar

Thursday, October 4, 2012 10:04 AM

Global healthcare company Sanofi has signed an agreement to acquire Genfar, a pharmaceuticals manufacturer headquartered in Bogota, Colombia. With this acquisition, Sanofi will expand its portfolio of affordable pharmaceuticals in Latin America.

More... »


CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

February 25

Analysts: With market anticipation of Quintiles IPO, other CROs could soon file to go public

National Clinical Trial Network aims to link sponsors, minority patients for trials and access to new therapies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Sites rate the best
sponsors of 2013

Largest survey response ever puts Biogen Idec, Forest Labs, Bayer at top

As CRO industry
turns 30, a look back
at modest beginnings

Phenomenal growth, strategic partnering highlight evolution
of CROs

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Sized out of big deals,
mid-tier CROs still thriving

Finding market niches, strategies to stay vital in changing research enterprise

Industry leaders embrace disruptive innovations
Despite resistance to change, many exploring data sharing, open-source collaboration

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs